The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.
13-Jan-2016 - The Pfizer-Allergan $160bn merger will create the world’s largest pharma company but potentially not for long, as the two CEOs discuss breaking the entity up in 2018.
15-Dec-2015 - Sun Pharma has announced it will divest a plant in Ohio to further consolidate manufacturing operations following its $4bn acquisition of Ranbaxy.
30-Nov-2015 - Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established...
12-Nov-2015 - Pfizer’s manufacturing network would stretch beyond 100 sites if a merger deal with Allergan is reached.
10-Nov-2015 - Unilife CEO Alan Shortall yesterday confirmed the drug delivery company is still “receiving interest from several parties under the strategic review process” and set a deadline of December 31 to...
09-Nov-2015 - AMRI attributed recent M&A activity to passing the $100m (€93m) quarterly sales milestone, reporting high double-digit growth across its API and small-scale manufacturing divisions.
22-Oct-2015 - As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say...
21-Oct-2015 - An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future....
16-Sep-2015 - Indian generics company Sun Pharma has made a $48m (€42m) offer for US eye drug maker InSite Vision and its delivery platform.
14-Sep-2015 - Mylan’s latest merger offer has been lambasted as “neither compelling, nor accretive” by Perrigo CEO Joseph Papa.
09-Sep-2015 - Horizon Pharma has renewed its efforts to take over pain and neurology firm Depomed for approximately $1.68bn (€1.5bn).
08-Sep-2015 - Cipla and Lannett have expanded their presence in the mid-sized US generics space through acquisitions totalling over $1.5bn.
25-Aug-2015 - Mylan will run Perrigo as a wholly-owned subsidiary if it acquires between 50-80% of shares, the firm has clarified.
24-Aug-2015 - Pfizer has received the final regulatory clearances to acquire Hospira but the US FTC says it must divests four sterile injectable products.
17-Aug-2015 - An SEC filing reveals Merck has cut 29,160 jobs in five years, and over 2,500 more may be on the way.
17-Aug-2015 - The huge former Ben Venue injectables manufacturing plant in Ohio that became the center of controversy over drug shortages a few years ago remains off line, and the company that...
30-Jul-2015 - Industry headhunters have picked their top CEOs in European pharma, saying the most successful investors keep chief execs in place even through hard times.
28-Jul-2015 - Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.
27-Jul-2015 - Teva has struck a deal to buy Allergan’s generics business a week after its persistent attempts to acquire Mylan fell through.
21-Jul-2015 - Celgene will take over a Merck & Co. facility in Summit, New Jersey which had been earmarked for closure.
20-Jul-2015 - Torrent Pharma has added two facilities to its network through the acqusition of Zyg Pharma from the Encore Group.
16-Jul-2015 - Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.
30-Jun-2015 - The proposed Perrigo merger with Mylan would be of no benefit to either firm in the “highly competitive” OTC sector, according to financial analysts BMO.
25-Jun-2015 - Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells in-Pharmatechnologist.com.
18-Jun-2015 - Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.